# A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct05299424/  
OnCo record `nct05299424` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CM336_group 1 in multiple myeloma, run by Keymed Biosciences Co.Ltd, now recruiting.

## Summary

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05299424 by Keymed Biosciences Co.Ltd, with 48 participants planned, started 2022-08-09 and due to reach its primary completion in 2026-12. Interventions recorded: CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b and CM336_group 4a.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05299424
- Phase: 1/2
- Setting: A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Keymed Biosciences Co.Ltd
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT05299424: https://clinicaltrials.gov/study/NCT05299424

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Keymed Biosciences (KYM Biosciences)](https://onco.cc/companies/keymed/)

---
JSON: https://onco.cc/api/v1/entities/nct05299424.json